Please assess the completion status of the following clinical trial:

Trial Title: A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed solid tumors that are metastatic or unrespectable for which carboplatin/gemcitabine is a treatment option.~* Eastern Cooperative Group performance score of 0 to 2.~* Adequate hematologic, hepatic and renal function~* Subject has received up to 2 DNA damaging or cytotoxic regimens in the past five years~Exclusion Criteria:~* Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within 28 days prior to study administration.~* Subjects with known history of brain metastases and primary CNS tumors.~* Hypersensitivity reactions to platinum compounds or gemcitabine.~* Clinically significant and uncontrolled major medical conditions~* Active malignancy within the past 5 years except for any cancer in situ cured or non-melanoma carcinoma of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).